Oculogenex wins first place in the International Winning Pitch Challenge prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Form of vaping may be banned for millions of Brits as part of new WHO plan
The World Health Organisation has reportedly written to governments highlighting the dangers posed by open-vaping – but the supposed ban proposals have been criticised
Updated
Vaping could be outlawed in Britain, it is claimed (Image: Getty Images/iStockphoto)
The Daily Star s FREE newsletter is spectacular! Sign up today for the best stories straight to your inboxInvalid EmailSomething went wrong, please try again later.
Sign up today!
When you subscribe we will use the information you provide to send you these newsletters. Sometimes they’ll include recommendations for other related newsletters or services we offer. OurPrivacy Noticeexplains more about how we use your data, and your rights. You can unsubscribe at any time.
E-Mail
LOS ANGELES (February 10, 2021) The Lundquist Institute has received a $1.75 million grant from the Steven & Alexandra Cohen Foundation to fund a multi-site clinical trial to evaluate the efficacy and safety of the compound psilocybin in individuals with severe psychological distress associated with a terminal medical illness. The grant will also support education and outreach programs related to the use of psilocybin within the field of palliative care. This innovative and first-of-its-kind psychedelic study will be conducted at several leading medical schools and cancer centers across the United States, including Harbor-UCLA Medical Center. This project has the potential to help so many people during one of the most stressful times in a person s and family s life, said Alexandra Cohen, President, Steven & Alexandra Cohen Foundation. We are pleased to support the Lundquist Institute in their efforts to explore the benefits of psychedelics for patients with terminal
E-Mail
Dr. Ruey-Kang Chang, Investigator at The Lundquist Institute, has received the highly-respected Tibbets Award from the Small Business Administration (SBA) for founding QT Medical to create a new system that identifies countless cardiac conditions, from newborns to adults - not only enabling early treatment, but empowering at-home care.
Dr. Chang, a pediatric cardiologist, was frustrated with the impracticality of conducting Electrocardiograms (ECGs) on his youngest patients. As a result, Dr. Chang began designing and testing QT ECG, a new system for babies that can detect Long QT Syndrome early and enable access to proper treatment. QT ECG is a hospital-quality 12-lead ECG device cleared by the Food and Drug Administration (FDA) for home-use cardiac self-monitoring under a physician s guidance. QT ECG is a complete ECG platform that includes both the device components as well as apps for smart devices, preliminary computer interpretation, and Health Insurance Portability
Amgen Inc. on Wednesday announced it will sponsor BioLabs LA at the Lundquist Institute, a biotech co-working space in Torrance, via a three-year Golden Ticket program.
Through the program, Thousand Oaks-based Amgen will launch one Golden Ticket award each year of its sponsorship, providing the winning startup with one year of lab space at BioLabs LA and access to lab infrastructure, programming and business development mentorship.
The sponsorship’s monetary value was not disclosed.
“Recognizing the growing biotech ecosystem in Southern California, Amgen’s sponsorship of the Golden Ticket with BioLabs aims to further foster early-stage life science companies right in the backyard of Amgen’s headquarters,” Dr. Philip Tagari, vice president of therapeutic discovery at Amgen, said in a statement.